Synthesis and biological evaluation of 2-amino-3-(3′,4′, 5′-trimethoxybenzoyl)-5-aryl thiophenes as a new class of potent antitubulin agents

Journal of Medicinal Chemistry

Volumn 49, Issue 13, 2006, Pages 3906-3915

  Romagnoli, Romeo ^a   Baraldi, Pier Giovanni ^a   Pavani, Maria Giovanna ^a   Tabrizi, Mojgan Aghazadeh ^a   Preti, Delia ^a   Fruttarolo, Francesca ^a   Piccagli, Laura ^a   Jung, M Katherine ^b   Hamel, Ernest ^c   Borgatti, Monica ^a   Gambari, Roberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 3 (3',4',5' TRIMETHOXYBENZOYL) 5 PHENYLTHIOPHENE; [2 AMINO 5 (4 FLUOROPHENYL)THIOPHEN 3 YL](3,4,5 TRIMETHOXYPHENYL)METHANONE; [2 AMINO 5 (4 METHOXYPHENYL)THIOPHEN 3 YL](3,4,5 TRIMETHOXYPHENYL)METHANONE; [2 AMINO 5 (4 METHYLPHENYL)THIOPHEN 3 YL](3,4,5 TRIMETHOXYPHENYL)METHANONE; ANTINEOPLASTIC AGENT; ANTITUBULIN AGENT; COLCHICINE; COMBRETASTATIN A4; PODOPHYLLOTOXIN; THIOPHENE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN K 562; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; LEUKEMIA L 1210; MICROTUBULE ASSEMBLY; MOLECULAR MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOATES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLCHICINE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MICE; MODELS, MOLECULAR; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES; TUBULIN; TUBULIN MODULATORS;

EID: 33745659825     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060355e     Document Type: Article

References (47)

1. Gourley, M.; Williamson, J. S. Angiogenesis: new targets for the development of anticancer chemotherapies. Curr. Pharm. Des. 2000, 6, 417-439.
2. (a) Hamel, E. Antimitotic natural products and their interactions with tubulin. Med. Chem. Rev. 1996, 16, 207-231.
3. (b) Jordan, A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T.; Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med. Res. Rev. 1998, 18. 259-296.
4. (c) Li, Q.; Sham, H. L. Discovery and development of antimitotic agents that inhibit tubulin polymerization for the treatment of cancer. Expert Opin. Ther. Pat. 2002, 12, 1663-1702.
5. (d) Jordan, M. A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. 2002, 2, 1-17.
6. (a) Thorpe, P. E.; Chaplin, D. J.; Blakey, D. C.; The first international conference on vascular targeting: meeting overview. Cancer Res. 2003, 63, 1144-1147.
7. (b) Tozer, G. M.; Kanthou, C.; Parkins, C. S.; Hill, S. A. The biology of the combretastatins as tumor vascular targeting agents. Int. J. Exp. Pathol. 2002, 83, 21-38.
8. Pettit, G. R.; Singh, S. B.; Hamel, E.; Lin, C. M.; Alberts, D. S.; Garcia-Kendall, D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experentia 1989, 45, 209-211.
9. Lin, C. M.; Ho, H. H.; Pettit, G. R.; Hamel, E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989, 28, 6984-6991.
10. (a) Pettit, G. R.; Temple, C., Jr.; Narayanan, V. L.; Varma, R.; Boyd, M. R.; Rener, G. A.; Bansal, N. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anti-Cancer Drug Des. 1995, 10, 299-309.
11. (b) Chaplin, D. J.; Pettit, G. R.; Hill, S. A. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 1999, 19, 189-195.
12. (c) Grosios, K.; Holwell, S. E.; McGown, A. T.; Pettit, G. R.; Bibby, M. C. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer 1999, 81, 1318-1327.
13. Nam, N. H. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr. Med. Chem. 2003, 10, 1697-1722.
14. Pettit, G. R.; Toki, B.; Herald, D. L.; Verdier-Pinard, P.; Boyd, M. R.; Hamel, E.; Pettit, R. K. Antineoplastic agent. 379. Synthesis of phenstatin phosphate. J. Med. Chem. 1998, 41, 1688-1695.
15. (a) Liou, J. P.; Chang, C. W.; Song, J. W.; Yang, Y. N.; Yeh, C. F.; Tseng, H. Y.; Lo, Y. K.; Chang, Y. L.; Chang, C. M.; Hsieh, H. P. Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. J. Med: Chem. 2002, 45, 2556-2572.
16. (b) Hsieh, H. P.; Liou, J. P.; Lin, Y. T.; Mahindroo, N.; Chang, Y. L.; Yang, Y. N.; Chern, S. S.; Tan, U.K.; Chang, C. W.; Chen, T. W.; Lin, C. H.; Chang, Y. Y.; Wang, C. C. Structure-activity and crystal lographic analysis of benzophenone derivatives - the potential anticancer agents. Bioorg. Med. Chem. Lett. 2003, 13, 101-105.
17. Liou, J. P.; Chang, J. Y.; Chang, C. W.; Chang, C. Y.; Maindroo, N.; Kuo, F. M.; Hsieh, H. P. Synthesis and structure-activity relationship of 3-aminobenzophenones as antimitotic agents. J. Med. Chem. 2004, 47, 2897-2905.
18. Cushman, M.; Nagarathnam, D.; Gopal, D.; Lin, C. M.; Hamel, E. Synthesis and evaluation of analogues of (Z)-1-(4-methoxyphenyl)-2-(3,4,5- trimethoxyphenyl)ethane as potential cytotoxic and antimitotic agents. J. Med. Chem. 1992, 35, 2293-2306.
19. Gewald, K.; Schinke, E.; Böettcher, H. Heterocycles from CH-acidic nitriles. VIII. 2-Aminothiophenes from methylene-active nitriles, carbonyl compounds and sulfur. Chem. Ber. 1966, 99, 94-100.
20. For the synthesis of 10a see: Seneci, P.; Nicola, M.; Inglesi, M.; Vanotti, E.; Resnati, G. Synthesis of mono- and disubstituted 1H-imidazo[1,2-b] pyrazoles. Synth. Commun. 1999, 2, 311-341.
21. Compound 10b was synthesized using the following reference: Baba, A.; Mori, A.; Yasuma, T.; Unno, S., Makino, H.; Sohda, T. Studies on disease-modifying antirheumatic drugs. IV. Synthesis of novel thieno[2,3-b:5,4-c′]dipyridine derivatives and their anti-inflammatory effect. Chem. Pharm. Bull. 1999, 47, 993-999. Compound 10c was commercially available.
22. Tinney, F. J.; Sanchez, J. P.; Nogas, J. A. Synthesis and pharmacological evaluation of 2,3-dihydro-1H-thieno[2,3-e][1,4]diazepines. J. Med. Chem. 1974, 17, 624-630.
23. Vamecq, J.; Bac, P.; Herrenknecht, C.; Maurois, P.; Delcourt, P.; Stables, J. P. Synthesis and anticonvulsant and neurotoxic properties of substituted N-phenyl derivatives of the phthalimide pharmacophore. J. Med. Chem. 2000, 43, 1311-1319.
24. Karlsson, O. Bromination of some heteroaromatic acyl compounds with aqueous bromine/sodium acetate. Synth. Commun. 1981, 11, 29-34.
25. Andersen, K. E.; Begtrup, M.; Chorghade, M. S.; Mukund, S.; Lee, E. C.; Lau, J.; Lundt, B. F.; Petersen, H.; Sorensen P. O.; Thogersen H. The synthesis of novel GABA uptake inhibitors. Part 2. Synthesis of 5-hydroxytiagabine, a human metabolite of the GABA reuptake inhibitor tiagabine. Tetrahedron 1994, 50, 8699-8710.
26. Shieh, W. C.; Carlson, J. A. A simple asymmetric synthesis of 4-arylphenylalanines via palladium-catalyzed cross-coupling reaction of arylboronic acids with tyrosine triflate. J. Org. Chem. 1992, 57, 379-381.
27. For a general review on palladium cross-coupling reactions see Miyaura, N.; Suzuki, A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem. Rev. 1995, 95, 2457-2483.
28. Gacek, M.; Undheim, K.; Hakansson, R. N-quaternary compounds. 43. Synthesis and circular dichroism of α-amino and α-N,N,N- trimethylammonio acid amides. Tetrahedron 1977, 33, 589-592.
29. Gambari, R.; Feriotto, G.; Rutigliano, C.; Bianchi, N.; Mischiati, C. Biospecific interaction analysis (BIA) of low-molecular weight DNA-binding drugs. J. Pharmacol. Exp. Ther. 2000, 294, 370-377.
30. (a) Bianchi, N.; Ongaro, F.; Chiarabelli, C.; Gualandi, L.; Mischiati, C.; Bergamini, P.; Gambari, R. Induction of erythroid differentiation of human K562 cells by cisplatin analogs. Biochem. Pharmacol. 2000, 60, 31-40.
31. (b) Perchellet, E. M.; Magill, M. J.; Huang, X.; Dalke, D. M.; Hua, D. H.; Perchellet J. P. 1,4-Anthraquinone: an anticancer drug that blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of L1210 leukemic cells in the same nanomolar range as daunorubicin in vitro. Anti-Cancer Drugs 2000, 11, 339-352.
32. (c) Grzanka, A.; Grzanka, D.; Orlikowska, M. Cytoskeletal reorganization during process of apoptosis induced by cytostatic drugs in K-562 and HL-60 leukemia cell lines Biochem. Pharmacol. 2003, 66, 1611-1617.
33. (a) Hamel, E. Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin. Cell Biochem. Biophys. 2003, 38, 1-21.
34. (b) Verdier-Pinard, P.; Lai J.-Y.; Yoo, H.-D.; Yu, J.; Marquez, B.; Nagle D. G.; Nambu, M.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol. Pharmacol. 1998, 53, 62-67.
35. Bailly, C.; Bal, C.; Barbier, P.; Combes, S.; Finet, J. P.; Hildebrand, M. P.; Peyrot, V.; Wattez, N. Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. J. Med. Chem. 2003, 46, 5437-44.
36. Pellegrini, F.; Budman, D. R. Tubulin function, action of antitubulin drugs and new drug development. Cancer Invest. 2005, 23, 264-73.
37. Wall, N. R.; Mohammad, R. M., Al-Katib, A. M. Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line. Leuk. Res. 1999 23, 881-888.
38. Huang, D. M.; Guh, J. H.; Huang, Y. T.; Chueh, S. C.; Chiang, P. C.; Teng, C. M. Induction of mitotic arrest and apoptosis in human prostate cancer PC-3 cells by evodiamine. J. Urol. (Baltimore) 2005, 173, 256-61.
39. Ravelli, R. B. G.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar. S.; Sobel, A.; Knossow, M. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004, 428, 198-202.
40. Goodsell, D. S.; Morris, G. M.; Olson, A. J. Automated docking of flexible ligands: Applications of AutoDock. J. Mol. Recognit. 1996, 9, 1-5.
41. De Martino, G.; La Regina, G.; Coluccia, A.; Edler, M. C.; Barbera, M. C.; Brancale, A.; Wilcox, E.; Hamel, E.; Artico, M.; Silvestri, R. Arylthioindoles, potent inhibitors of tubulin polymerization. J. Med. Chem. 2004, 47, 6120-6123
42. De Martino, G.; Edler, M. C.; La Regina, G.; Coluccia, A.; Barbera, M. C.; Barrow, D.; Nicholson, R. I.; Chiosis, G.; Brancale, A.; Hamel, E.; Artico, M.; Silvestri, R. New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies. J. Med. Chem. 2006, 49, 947-954.
43. Hamel, E.; Lin, C. M. Separation of active tubulin and microtubule-associated proteins by ultracentrifugation, and isolation of a component causing the formation of microtubule bundles. Biochemistry 1984, 23, 4173-4184.
44. Gambari, R.; Marks, P. A.; Rifkind, R. A. Murine erythroleukemia cell differentiation: relationship of globin gene expression and of prolongation of G1 to inducer effects during G1/early S. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 4511-4515.
45. Gambari, R.; Terada, M.; Bank, A.; Rifkind, R. A.; Marks, P. A. Synthesis of globin mRNA in relation to the cell cycle during induced murine erythroleukemia differentiation. Proc. Natl. Acad. Sci. U.S.A. 1978, 75, 3801-3804.
46. Penolazzi, L.; Lambertini, E.; Borgatti, M.; Piva, R.; Cozzani, M.; Giovannini, I.; Naccari, R.; Siciliani, G.; Gambari, R: Decoy oligodeoxynucleotides targeting NF-kappaB transcription factors: induction of apoptosis in human primary osteoclasts. Biochem. Pharmacol. 2003, 66, 1189-1198.
47. Dewar, M.; Zoebish, G.; Healy, E. AM1: A new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 1985, 107, 3902-3909.